US · SRZN · BIOTECHNOLOGY
Surrozen, Inc. (SRZN) intrinsic value and stock valuation
$28.46as of 2026-11-21 · Mkt cap 164.13M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Surrozen, Inc. DCF and intrinsic value
InvestorsCraft values SRZN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from SRZN’s statements →
Surrozen, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.48M | $10.7M | $0.00 | $12.5M | $0.00 |
| Operating income | -$-42.09M | -$-25.54M | -$-45.78M | -$-44.34M | -$-54.39M |
| Net income | -$-242.03M | -$-63.56M | -$-43.04M | -$-36M | -$-52.51M |
| EPSd | -$-32.36M | -$-21.69M | -$-21.31M | -$-15.58M | -$-22.44M |
| Operating cash flow | -$-30.24M | -$-17.63M | -$-40.36M | -$-44.15M | -$-48.81M |
| Capital expenditure | -$-130K | -$-30K | -$-400K | -$-730K | -$-1.27M |
| Free cash flow | -$-30.37M | -$-17.65M | -$-40.76M | -$-44.87M | -$-50.08M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M |
| Total debt | $6.64M | $8.47M | $3.38M | $5.6M | $7.79M |
| Net debt | -$-82.61M | -$-26.1M | -$-32.66M | -$-19.09M | -$-25.3M |
| Total equity | -$-187.76M | -$-21.38M | $37.9M | $76M | $109.7M |
| Cash and short-term investments | $89.3M | $34.6M | $36M | $75.8M | $101.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.48M | $10.7M | $0.00 | $12.5M | $0.00 |
| Cost of revenue | $540K | $0.00 | $27.2M | $3.27M | $3.3M |
| Gross profit | $2.94M | $10.7M | -$-27.23M | $9.23M | -$-3.3M |
| Research and development expenses | $29.4M | $21.1M | $27.2M | $37M | $36.9M |
| Selling, general and administrative expenses | $16.2M | $15.1M | $15.8M | $19.8M | $14.2M |
| Other expenses | -$-540K | $0.00 | -$-24.48M | -$-3.27M | $0.00 |
| Operating expenses | $45M | $36.2M | $18.6M | $53.6M | $51.1M |
| Cost and expenses | $45.6M | $36.2M | $45.8M | $56.8M | $54.4M |
| Interest income | $3.02M | $1.69M | $2.34M | $780K | $70K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $540K | $1.44M | $1.91M | $1.96M | $3.3M |
| Ebitda | -$-241.49M | -$-62.12M | -$-41.13M | -$-34.05M | -$-51.35M |
| Operating income | -$-42.09M | -$-25.54M | -$-45.78M | -$-44.34M | -$-54.39M |
| Total other income/expenses, net | -$-199.93M | -$-38.02M | $2.74M | $8.34M | -$-260K |
| Income before tax | -$-242.03M | -$-63.56M | -$-43.04M | -$-36M | -$-54.65M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-242.03M | -$-63.56M | -$-43.04M | -$-36M | -$-52.51M |
| Weighted average shares outstanding | $7.48M | $2.93M | $2.02M | $2.31M | $2.34M |
| Weighted average diluted shares outstanding | $7.48M | $2.93M | $2.02M | $2.31M | $2.34M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $89.3M | $34.6M | $36M | $75.8M | $101.9M |
| Net receivables | $210K | $2.54M | $2.15M | $1.98M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $91.6M | $38.9M | $41.1M | $81.3M | $105.2M |
| Property, plant and equipment, net | $6.43M | $8.36M | $3.86M | $6.9M | $9.38M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $690K | $0.00 | $690K | $0.00 | $21.7M |
| Total non-current assets | $7.17M | $9.54M | $4.95M | $8.13M | $32M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M |
| Accounts payable | $730K | $310K | $530K | $660K | $2.72M |
| Short-term debt | $1.29M | $1.83M | $2.5M | $2.23M | $2.19M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $9.93M | $7.32M | $7.15M | $9.73M | $13.6M |
| Long-term debt | $5.35M | $6.64M | $880K | $3.38M | $5.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $276.6M | $62.5M | $1M | $3.7M | $13.9M |
| Capital lease obligations | $6.64M | $8.47M | $3.38M | $5.6M | $7.79M |
| Total liabilities | $286.5M | $69.9M | $8.14M | $13.4M | $27.5M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-527.28M | -$-285.26M | -$-221.69M | -$-178.65M | -$-142.65M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-240K | -$-120K |
| Total equity | -$-187.76M | -$-21.38M | $37.9M | $76M | $109.7M |
| Total investments | $690K | $0.00 | $690K | $51.2M | $90.4M |
| Total debt | $6.64M | $8.47M | $3.38M | $5.6M | $7.79M |
| Net debt | -$-82.61M | -$-26.1M | -$-32.66M | -$-19.09M | -$-25.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-242.03M | -$-63.56M | -$-43.04M | -$-36M | -$-54.65M |
| Depreciation and amortization | $540K | $1.44M | $1.91M | $1.96M | $2.07M |
| Stock-based compensation | $3.83M | $4.11M | $4.37M | $4.52M | $2.32M |
| Change in working capital | $3.15M | -$-840K | -$-3.93M | -$-8.42M | -$-220K |
| Accounts receivable | $2.33M | -$-500K | $0.00 | -$-1.98M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $140K | -$-230K | -$-130K | -$-2.04M | $860K |
| Net cash provided by operating activities | -$-30.24M | -$-17.63M | -$-40.36M | -$-44.15M | -$-48.81M |
| Investments in property, plant and equipment | -$-130K | -$-30K | -$-400K | -$-730K | -$-1.27M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-39.04M | $0.00 |
| Net cash used for investing activities | -$-130K | -$-30K | $51.7M | $38.3M | -$-77.71M |
| Common stock issued | $85.1M | $16M | $280K | $40K | $124.2M |
| Common stock repurchased | $0.00 | $0.00 | -$0.00 | -$-2.61M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $85.1M | $16.2M | $280K | -$-2.56M | $124.6M |
| Net change in cash | $54.7M | -$-1.48M | $11.6M | -$-8.4M | -$-1.89M |
| Cash at end of period | $89.9M | $35.3M | $36.7M | $25.1M | $33.5M |
| Operating cash flow | -$-30.24M | -$-17.63M | -$-40.36M | -$-44.15M | -$-48.81M |
| Capital expenditure | -$-130K | -$-30K | -$-400K | -$-730K | -$-1.27M |
| Free cash flow | -$-30.37M | -$-17.65M | -$-40.76M | -$-44.87M | -$-50.08M |
Line items
Line items
Line items
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
- CEO
- Craig Parker
- Employees
- 44
- Beta
- 0.51
Explore
Frequently asked questions
What is the intrinsic value of Surrozen, Inc. (SRZN)?
Surrozen, Inc. (SRZN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SRZN undervalued?
SRZN trades at a price of $28.46 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.